Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (\<140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitrated over a 6 week period until target blood pressure (\<140/90mmHg) is met. The primary objective of the study is to compare the proportion of subjects who achieve target blood pressure after 6 weeks of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
348
carvedilol CR + lisinopril given as separate pills
lisinopril plus placebo to match carvedilol CR
Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment
Sitting cuff blood pressure was calculated as the mean of three measurements taken approximately 2 minutes apart, and before the morning dose.
Time frame: Week 6
Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) and Sitting Diastolic Blood Pressure (sDBP) at Week 6
Mean change was calculated as Week 6 values minus Baseline values.
Time frame: Baseline and Week 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Glendale, Arizona, United States
GSK Investigational Site
Goodyear, Arizona, United States
GSK Investigational Site
Litchifield Park/Arizona, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Beuna Park, California, United States
GSK Investigational Site
Fountain Valley, California, United States
...and 66 more locations